Boston Scientific Corporation (LON:0HOY)
Market Cap | 108.38B |
Revenue (ttm) | 13.50B |
Net Income (ttm) | 1.83B |
Shares Out | n/a |
EPS (ttm) | 1.23 |
PE Ratio | 59.28 |
Forward PE | 30.94 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,948 |
Average Volume | 21,141 |
Open | 96.76 |
Previous Close | 96.45 |
Day's Range | 96.69 - 97.65 |
52-Week Range | 80.50 - 109.51 |
Beta | 0.61 |
RSI | 42.12 |
Earnings Date | Oct 22, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
November 28th Options Now Available For Boston Scientific (BSX)
Investors in Boston Scientific Corp. (Symbol: BSX) saw new options begin trading today, for the November 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BS...

4 Top AI-Powered Healthcare Stocks
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthc...

Boston Scientific: Not In The Most Resolute State As It Approaches Q3 Earnings
Read here for Boston Scientific (BSX) stock's outlook ahead of Q3 earnings, assess valuation, margin pressures, and acquisition impacts.
Evercore ISI Revises Boston Scientific (BSX) Price Target to $110 | BSX Stock News
Evercore ISI Revises Boston Scientific (BSX) Price Target to $110 | BSX Stock News
Boston Scientific (BSX) Target Price Cut by Evercore ISI Amid Market Concerns
Boston Scientific (BSX) Target Price Cut by Evercore ISI Amid Market Concerns
The Zacks Analyst Blog Highlights Boston Scientific, Union Pacific, Realty Income and Weyco
BSX, UNP, O, and WEYS stand out with strong sector performance, resilient cash flows, and strategic growth moves, despite headwinds from tariffs, e-commerce, and macro uncertainties.
Top Research Reports for Boston Scientific, Union Pacific & Realty Income
Boston Scientific gains from MedSurg and cardiovascular strength, while Union Pacific and Realty Income face mixed headwinds.
BSX Factor-Based Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy ...
Boston Scientific (BSX) Analyst Rating Update: Canaccord Genuity Raises Price Target | BSX ...
Boston Scientific (BSX) Analyst Rating Update: Canaccord Genuity Raises Price Target | BSX Stock News
Boston Scientific (BSX) Acquires BioEnvelope Business for $88M
Boston Scientific (BSX) Acquires BioEnvelope Business for $88M
Baird Raises Price Target for Boston Scientific (BSX) to $128.00 | BSX Stock News
Baird Raises Price Target for Boston Scientific (BSX) to $128.00 | BSX Stock News

Boston Scientific To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Wednesday
Full story available on Benzinga.com
Boston Scientific (BSX): Analyst Mike Matson Reiterates Buy Rating | BSX Stock News
Boston Scientific (BSX): Analyst Mike Matson Reiterates Buy Rating | BSX Stock News
Boston Scientific Corporation (BSX) 2025 Investor Day Call (Transcript)
Discover Boston Scientific's latest investor insights, 3-year growth strategies

Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript
Boston Scientific Corporation (NYSE:BSX) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President...
If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 20.24%. Currently, Boston Scientific has a marke...

Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...

Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Noteworthy Tuesday Option Activity: BSX, FDX, PYPL
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Boston Scientific Corp. (Symbol: BSX), where a total of 39,928 contracts have traded so far, rep...
Relative Strength Alert For Boston Scientific
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Boston Scientific Breaks Below 200-Day Moving Average - Notable for BSX
In trading on Monday, shares of Boston Scientific Corp. (Symbol: BSX) crossed below their 200 day moving average of $100.54, changing hands as low as $100.39 per share. Boston Scientific Corp. shares ...
Peter Lynch Detailed Fundamental Analysis - BSX
Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy ...
Pre-tax profits at Irish arm of Boston Scientific increase by 52pc to $111m
Pre-tax profits at the main Irish arm of medical device manufacturer Boston Scientific last year increased by 52pc to $111.15m (94.8m).
Elutia (ELUT) Sells Bioenvelopes to Boston Scientific
Elutia (ELUT) Sells Bioenvelopes to Boston Scientific
Boston Scientific (BSX) Purchases Elutia's Bioenvelope Assets in $88 Million Deal
Boston Scientific (BSX) Purchases Elutia's Bioenvelope Assets in $88 Million Deal